Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shameen Afif-Rider

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Lab Animal|August 23, 2019
Perception, deception, distrust - Oh My!Erin Straley, Shameen Afif-Rider
Lab Animal|April 21, 2012
Supplementing a training procedure with the use of a cadaver. Response to protocol review scenario: Passing the buckDonna L Goldsteen, Shameen Afif-Rider, Youngmi Girard
Regulatory Toxicology and Pharmacology : RTP|May 11, 2021
The Evolution of SEND at AstraZenecaClaire Kent, Brett Coupland, Claire Barnard, et al.
Molecular Cancer Therapeutics|February 1, 2023
Comparison of Pyrrolobenzodiazepine Dimer Bis-imine versus Mono-imine: DNA Interstrand Cross-linking, Cytotoxicity, Antibody-Drug Conjugate Efficacy and ToxicityArnaud C Tiberghien, Balakumar Vijayakrishnan, Arman Esfandiari, et al.
Molecular Cancer Therapeutics|July 6, 2022
Efficacy, Tolerability, and Pharmacokinetic Studies of Antibody-Drug Conjugates Containing a Low-Potency Pyrrolobenzodiazepine DimerStephen J Gregson, Kathryn Pugh, Neki Patel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2017
Fractionated Dosing Improves Preclinical Therapeutic Index of Pyrrolobenzodiazepine-Containing Antibody Drug ConjugatesMary Jane Masson Hinrichs, Pauline M Ryan, Bo Zheng, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Lab Animal|August 23, 2019
Perception, deception, distrust - Oh My!Erin Straley, Shameen Afif-Rider
Lab Animal|April 21, 2012
Supplementing a training procedure with the use of a cadaver. Response to protocol review scenario: Passing the buckDonna L Goldsteen, Shameen Afif-Rider, Youngmi Girard
Regulatory Toxicology and Pharmacology : RTP|May 11, 2021
The Evolution of SEND at AstraZenecaClaire Kent, Brett Coupland, Claire Barnard, et al.
Molecular Cancer Therapeutics|February 1, 2023
Comparison of Pyrrolobenzodiazepine Dimer Bis-imine versus Mono-imine: DNA Interstrand Cross-linking, Cytotoxicity, Antibody-Drug Conjugate Efficacy and ToxicityArnaud C Tiberghien, Balakumar Vijayakrishnan, Arman Esfandiari, et al.
Molecular Cancer Therapeutics|July 6, 2022
Efficacy, Tolerability, and Pharmacokinetic Studies of Antibody-Drug Conjugates Containing a Low-Potency Pyrrolobenzodiazepine DimerStephen J Gregson, Kathryn Pugh, Neki Patel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2017
Fractionated Dosing Improves Preclinical Therapeutic Index of Pyrrolobenzodiazepine-Containing Antibody Drug ConjugatesMary Jane Masson Hinrichs, Pauline M Ryan, Bo Zheng, et al.
Pageof 1